Jubilant Pharmova Passes FDA Audit, Expands R&D with Pierre Fabre

26 Sep 2024 , 07:42 PM

Jubilant Pharmova Ltd announced the successful completion of an FDA audit for its subsidiary, Jubilant HollisterStier LLC, on September 26, 2024.

The audit was conducted from September 18 to 25, 2024, at two facilities located in Spokane, Washington: the Allergy Immunotherapy Facility and the Contract Manufacturing Facility. Jubilant HollisterStier LLC operates under Jubilant Pharma Holding Inc., a subsidiary of Jubilant Pharma Ltd, Singapore.

This FDA audit confirms compliance with regulatory standards, enhancing the credibility of Jubilant’s operations in the United States.

In a separate announcement last month, Jubilant Pharmova revealed its subsidiary, Jubilant Biosys Ltd, plans to acquire an 80% stake in Pierre Fabre Laboratories’ R&D Centre in Saint Julien, France.

The acquisition is valued at approximately €4.4 million over two years and will be executed through a newly incorporated entity in France. This strategic move aims to strengthen Jubilant Biosys’ capabilities in biologics and antibody-drug conjugates (ADCs).

The deal is subject to approval from Pierre Fabre and requires the completion of definitive agreements and standard closing conditions. These developments highlight Jubilant Pharmova’s commitment to expanding its global footprint and enhancing its research capabilities. The successful audit and strategic acquisitions position Jubilant Pharmova for future growth in the pharmaceutical sector.